Abstract 5769
Background
Information about chemotherapy is complex. Access to information prior to treatment enables patients to gain a better understanding of their condition, lessen their concerns and enables them to make informed choices about treatment. Traditionally chemotherapy education was provided by oncology clinical nurse specialists (CNS) on an individual basis to patients before they started chemotherapy. Increasing numbers of patients and reduced staff resources lead to problems maintaining service. The Irish Cancer Society’s Daffodil Centres are committed to quality improvement across cancer services available to those affected by cancer. Mater Misericordiae University Hospital (MMUH) and the Irish Cancer Society’s Daffodil Centre collaborated on a group chemotherapy initiative in 2012 initiated in response to a high demand for education services. After a successful pilot the programme is now running in 8 hospitals across Ireland. In 2018 342 group education sessions were held with 1713 attendees.
Methods
The Cancer Nurse in the Daffodil Centre facilitates this programme using educational tools including a specially produced audiovisual support (DVD) and short oral and practical demonstrations to assist different learning styles. To conclude the CNS meets with the patients to discuss their individual plan. All attendees are asked to complete an evaluation form which is inputted into a database and the results collated.
Results
1217 completed the evaluation out of 1713 attendees. A number of themes emerged including: • Welcoming • Good information • Allayed concerns • Empowerment. Acknowledgement of the expertise of the nurse and other allied healthcare professionals who present at the session – medical social workers and dietitians.
Conclusions
Overall satisfaction levels were very high in the programme including the information and content on the DVD and the information received and the way it was explained by the nurse. Of those who left comments they were very positive about the experience and for the opportunity to attend. By attending the session patients and their relative/friends were made to feel welcome. Their knowledge of chemotherapy and its side effects were greatly increased and their fears of commencing treatment were in many ways alleviated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract